Monopar Therapeutics’ (MNPR) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note published on Wednesday morning,Benzinga reports. BTIG Research currently has a $104.00 target price on the stock.

A number of other equities research analysts have also commented on MNPR. Barclays set a $125.00 price target on shares of Monopar Therapeutics and gave the company an “overweight” rating in a report on Monday, October 13th. Leerink Partners started coverage on shares of Monopar Therapeutics in a research report on Monday, November 10th. They issued an “outperform” rating and a $115.00 price objective on the stock. Leerink Partnrs upgraded shares of Monopar Therapeutics to a “strong-buy” rating in a report on Monday, November 10th. Jones Trading upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. Finally, Chardan Capital upped their price target on Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Sunday, November 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Monopar Therapeutics has a consensus rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Trading Up 1.3%

NASDAQ MNPR opened at $70.00 on Wednesday. The firm has a market cap of $467.60 million, a PE ratio of -20.35 and a beta of 1.46. Monopar Therapeutics has a 1-year low of $26.06 and a 1-year high of $105.00. The stock has a 50-day moving average of $74.62 and a 200-day moving average of $63.22.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). As a group, equities research analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Quan Anh Vu acquired 1,500 shares of the stock in a transaction on Friday, December 26th. The stock was acquired at an average cost of $69.95 per share, for a total transaction of $104,925.00. Following the completion of the acquisition, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at approximately $104,925. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MNPR. AlphaQuest LLC lifted its stake in shares of Monopar Therapeutics by 8.5% in the 3rd quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after purchasing an additional 151 shares during the period. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics in the third quarter worth $28,000. BNP Paribas Financial Markets lifted its position in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $34,000. Finally, JPMorgan Chase & Co. grew its position in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the period. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.